Alfonso E Bello

Summary

Publications

  1. ncbi request reprint Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature
    Alfonso E Bello
    University of Illinois College of Medicine at Chicago, Chicago, IL 60612, USA
    Curr Med Res Opin 22:2221-32. 2006
  2. ncbi request reprint Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications
    Alfonso E Bello
    College of Medicine, University of Illinois Chicago, Illinois Bone and Joint Institute, LLC, 2401 Ravine Way, Glenview, IL, USA
    Drug Saf 37:897-902. 2014
  3. ncbi request reprint Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials
    Jay L Goldstein
    Section of Digestive and Liver Diseases, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612 7323, USA
    J Rheumatol 32:111-7. 2005
  4. ncbi request reprint Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis
    Andrew Whelton
    Universal Clinical Research Center, Inc, and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21030 1603, USA
    Am J Cardiol 90:959-63. 2002
  5. ncbi request reprint Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study
    Gurkirpal Singh
    Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, Calif 94301, USA
    Am J Med 119:255-66. 2006

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature
    Alfonso E Bello
    University of Illinois College of Medicine at Chicago, Chicago, IL 60612, USA
    Curr Med Res Opin 22:2221-32. 2006
    ..The demand for treatments, both traditional and non-traditional, will continue to grow as the population ages...
  2. ncbi request reprint Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications
    Alfonso E Bello
    College of Medicine, University of Illinois Chicago, Illinois Bone and Joint Institute, LLC, 2401 Ravine Way, Glenview, IL, USA
    Drug Saf 37:897-902. 2014
    ..Clinicians should continue to use the current FDA NSAID labeling language to guide their decision making for individual patients until such time as the FDA makes changes. ..
  3. ncbi request reprint Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials
    Jay L Goldstein
    Section of Digestive and Liver Diseases, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612 7323, USA
    J Rheumatol 32:111-7. 2005
    ..To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)...
  4. ncbi request reprint Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis
    Andrew Whelton
    Universal Clinical Research Center, Inc, and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21030 1603, USA
    Am J Cardiol 90:959-63. 2002
    ..7%) compared with the celecoxib group (4.7%) (p <0.05). Thus, in patients with controlled hypertension on a fixed antihypertensive regimen, careful monitoring of BP is warranted after the initiation of celecoxib or rofecoxib therapy...
  5. ncbi request reprint Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study
    Gurkirpal Singh
    Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, Calif 94301, USA
    Am J Med 119:255-66. 2006
    ..To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with osteoarthritis...